22:19 , Jan 4, 2017 |  BC Week In Review  |  Clinical News

CardiAMP: Ph III CardiAMP Heart Failure started

BioCardia began the double-blind, sham-controlled, U.S. Phase III CardiAMP Heart Failure trial to evaluate CardiAMP in up to 260 patients. BioCardia Inc. (Pink:BCDA), San Carlos, Calif.  Product: CardiAMP  Business: Cardiovascular  Molecular target: NA  Description: High-dose autologous bone marrow-derived cells delivered...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

BioCardia, Tiger X Medical deal

Cardiovascular company BioCardia will reverse-merge with Tiger X Medical. The combined company will retain BioCardia’s name and will continue development of BioCardia’s CardiAMP cell therapy system, which is in Phase II trials to treat heart...